AstraZeneca has reported positive top-line results from the phase three studies deployed to investigate the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) to treat hospitalised adult patients with complicated intra-abdominal infections (cIAI).

CAZ-AVI is composed of cephalosporin (ceftazidime), an established treatment for serious bacterial infections and a next-generation non-beta lactam beta-lactamase inhibitor (avibactam).

The RECLAIM-1 and RECLAIM-2 phase three studies have evaluated the safety and efficacy of CAZ-AVI, which is under development with AstraZeneca to treat wide range of gram-negative bacterial infections that are becoming resistant to antibiotics.

"These results…highlight the potential for CAZ-AVI to provide a much-needed new treatment option for serious and life-threatening intra-abdominal infections."

AstraZeneca chief medical officer and global medicines development executive vice-president Briggs Morrison said: "We are very encouraged by these results which highlight the potential for CAZ-AVI to provide a much-needed new treatment option for serious and life-threatening intra-abdominal infections, especially where antibiotic resistance poses a threat to treatment."

In the studies, CAZ-AVI was administered intravenously as a two hour infusion (2,000mg / 500mg) plus metronidazole, compared to having meropenem administered intravenously as a 30 minute infusion (1g), in hospitalised adult patients with complicated intra-abdominal infections.

Following the agreement with US Food and Drug Administration (FDA) and European Medicines Agency (EMA), the date from the RECLAIM-1 and RECLAIM-2 studies were analysed as a single-pooled dataset.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CAZ-AVI has reached the objective of statistical non-inferiority compared to meropenem in both the phase three studies.

In addition, studies are initiated for CAZ-AVI in complicated urinary tract infections (cUTI), nosocomial pneumonia and for the treatment of cIAI and cUTI patients with ceftazidime-resistant infections.

AstraZeneca, along with Actavis’ wholly owned subsidiary Forest Laboratories, is developing CAZ-AVI. AstraZeneca holds the global rights to commercialise CAZ-AVI, while Forest holds the rights for North America.